Unknown

Dataset Information

0

Targeting ganglioside epitope 3G11 on the surface of CD4+ T cells suppresses EAE by altering the Treg/Th17 cell balance.


ABSTRACT: Loss of expression of the 3G11 epitope, present on disialoceramide that is predominantly found on CD4(+) T cells, has been associated with a regulatory T cell (Treg) phenotype and tolerance induction in experimental autoimmune encephalomyelitis (EAE). Here we report that treatment with anti-3G11 mAb shifts the immune response from pro-inflammatory to tolerogenic and suppresses both chronic-progressive and relapsing-remitting EAE. This therapeutic effect can be achieved at different stages of EAE. Treatment with anti-3G11 mAb increased the proportion of Foxp3(+)CD25(+)CD4(+) Tregs and IL-10 production while inhibiting production of pro-inflammatory cytokines and responsiveness to IL-2 and decreasing the proportion of T(h)17 cells. The effect of anti-3G11 mAb was diminished in IL-10(-/-) mice, indicating that this cytokine mediates some of its effects. As 3G11 belongs to the ganglioside family, which is expressed on the surface of both murine and human CD4(+) T cells, targeting this class of molecules may provide a novel approach for treating autoimmune diseases.

SUBMITTER: Zhao Z 

PROVIDER: S-EPMC2946215 | biostudies-literature | 2010 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Targeting ganglioside epitope 3G11 on the surface of CD4+ T cells suppresses EAE by altering the Treg/Th17 cell balance.

Zhao Zhao Z   Ciric Bogoljub B   Yu Shuo S   Zhang Guang-Xian GX   Rostami Abdolmohamad A  

International immunology 20100802 10


Loss of expression of the 3G11 epitope, present on disialoceramide that is predominantly found on CD4(+) T cells, has been associated with a regulatory T cell (Treg) phenotype and tolerance induction in experimental autoimmune encephalomyelitis (EAE). Here we report that treatment with anti-3G11 mAb shifts the immune response from pro-inflammatory to tolerogenic and suppresses both chronic-progressive and relapsing-remitting EAE. This therapeutic effect can be achieved at different stages of EAE  ...[more]

Similar Datasets

| S-EPMC4414149 | biostudies-literature
| S-EPMC7676685 | biostudies-literature
| S-EPMC4929289 | biostudies-literature
| S-EPMC8787365 | biostudies-literature
| S-EPMC8601377 | biostudies-literature
| S-EPMC4364395 | biostudies-literature
| S-EPMC3797729 | biostudies-literature
| S-EPMC7810881 | biostudies-literature
| S-EPMC7575723 | biostudies-literature
| S-EPMC5765124 | biostudies-literature